Ziconotide vs Cosyntropin
Head-to-head comparison of Ziconotide (ω-Conotoxin MVIIA (ziconotide)) and Cosyntropin (Cosyntropin (ACTH 1-24)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Ziconotide | Cosyntropin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | ω-Conotoxin MVIIA (ziconotide) | Cosyntropin (ACTH 1-24) |
| Molecular Weight | 2639.1 Da | 2933.3 Da |
| Half-Life | approximately 4.5 hours | ~10 min |
| Amino Acids | 25 | 24 |
| Typical Dose | 0.5-19.2 mcg/day | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary |
| Route | Intrathecal | IV|IM |
| Purity | ≥98% | ≥98% |
| Studies Count | 500 | 61 |
| Research Status | Approved | Clinical research |
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
Research Overview
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.